NCT05957510View on ClinicalTrials.gov

Safety and Efficacy Evaluation of Serplulimab Plus Chemo in SCLC Transformed From EGFR-mutated NSCLC After Treatment

PHASE2RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

July 10, 2023

Primary Completion Date

June 30, 2025

Study Completion Date

December 31, 2025

Conditions
Small-cell Lung Cancer
Interventions
DRUG

Serplulimab

serplulimab 300mg, d1, q3w, iv. etoposide 100 mg/m2, d1-3, q3w, iv. carboplatin AUC 5 (up to 750mg), d1, q3w, iv.

DRUG

SOC

the treatment recommended by the investigator

Trial Locations (1)

Unknown

RECRUITING

Guangdong Provincial Perople's Hospital, Guangzhou

All Listed Sponsors
collaborator

Guangdong Provincial People's Hospital

OTHER

lead

Guangdong Association of Clinical Trials

OTHER